Toray Industries has entered into a licensing-agreement collaboration with Bonac on nucleic-acid candidate BNC-1021. Under the agreement, Toray gains exclusive rights in Japan to develop, market, and manufacture (not including the bulk drug substance) idiopathic pulmonary-fibrosis candidate BNC-1021.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
804.2 JPY | +6.24% |
|
+5.28% | +9.70% |
05-27 | Toray Industries to Build Advanced Materials Production Plant in South Korea's Gumi City | MT |
05-22 | Immunis Partners with Toray to Reverse Sarcopenia | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.70% | 7.65B | |
+1.97% | 102B | |
-5.39% | 62.47B | |
+87.14% | 52.55B | |
+6.44% | 35.34B | |
+2.82% | 31.83B | |
+6.73% | 19.21B | |
+18.21% | 17.58B | |
+8.81% | 13.89B | |
+75.12% | 12.76B |
- Stock Market
- Equities
- 3402 Stock
- News Toray Industries, Inc.
- Toray Enters into Licensing Agreement with Bonac on Nucleic Medicine Targeting Idiopathic Pulmonary Fibrosis